Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21158Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsouli, S. | en |
| dc.contributor.author | Konitsiotis, S. | en |
| dc.date.accessioned | 2015-11-24T19:13:08Z | - |
| dc.date.available | 2015-11-24T19:13:08Z | - |
| dc.identifier.issn | 1742-1241 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21158 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antiparkinson Agents/*therapeutic use | en |
| dc.subject | Catechol O-Methyltransferase/antagonists & inhibitors | en |
| dc.subject | Dopamine Agonists/therapeutic use | en |
| dc.subject | Food-Drug Interactions | en |
| dc.subject | Humans | en |
| dc.subject | Monoamine Oxidase Inhibitors/therapeutic use | en |
| dc.subject | Parkinson Disease/*drug therapy | en |
| dc.subject | Practice Guidelines as Topic | en |
| dc.title | How should we treat a patient with early Parkinson's disease? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1111/j.1742-1241.2010.02371.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20653797 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1742-1241.2010.02371.x/asset/j.1742-1241.2010.02371.x.pdf?v=1&t=h0aqq148&s=2f72d143583ba70bda8b859d85c0d4452906cc3d | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | Parkinson's disease (PD) is characterised by the progressive degeneration of dopaminergic nigro-striatal neurons and severe striatal dopaminergic deficiency, leading to bradykinesia. Levodopa was the first drug used for PD treatment and is still considered the most useful weapon for the control of PD symptoms. However, levodopa treatment induces motor complications, which is considered as a major problem as the disease progresses. Dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase B inhibitors are some more recently developed drug categories which are expected to have a more favourable effect on motor complications. The choice of the best initial treatment in PD remains a controversial matter. Early therapeutic decisions in PD should balance the need for efficient short-term symptom control against long-term complication profile. The individualisation of the treatment seems to be the key for the best approach of early PD patients. | en |
| heal.journalName | Int J Clin Pract | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tsouli-2010-How should we treat.pdf | 165.69 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
